Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2024

Open Access 01-12-2024 | Parkinson's Disease | Study protocol

Efficacy of Wearable low-intensity pulsed Ultrasound treatment in the Movement disorder in Parkinson’s disease (the SWUMP trial): protocol for a single-site, double-blind, randomized controlled trial

Authors: Chuanyu Zhong, Ning Guo, Canfang Hu, Ruilong Ni, Xiaojie Zhang, Zheying Meng, Taotao Liu, Siqi Ding, Wanhai Ding, Yuwu Zhao, Li Cao, Yuanyi Zheng

Published in: Trials | Issue 1/2024

Login to get access

Abstract

Background

Parkinson’s disease (PD) is a progressive, neurodegenerative illness marked by the loss of dopaminergic neurons, causing motor symptoms. Oral levodopa replacement therapy remains the gold standard in the treatment of PD. It is, nevertheless, a symptomatic treatment. There is currently no effective treatment for PD. Therefore, new therapies for PD are highly desirable. Low-intensity pulsed ultrasound (LIPUS) has been shown to improve behavioral functions in PD animal models. It is a new type of neuromodulation approach that combines noninvasiveness with high spatial precision. The purpose of this study is to establish a new clinical protocol for LIPUS in the treatment of movement disorders in patients with PD.

Methods

This protocol is a single-site, prospective, double-blind, randomized controlled trial (RCT). Forty-eight participants with clinically confirmed PD will be randomly allocated to one of two groups: LIPUS group or sham group. All of the participants continue to use pharmacological therapy as a fundamental treatment. The primary outcome is the difference between groups from baseline to 4 months in the change in the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score (part III). The secondary outcomes include the rating scales such as the Mini-Mental State Examination (MMSE), and other three rating scales, and medical examinations including high-density electroencephalography (hdEEG) and functional magnetic resonance imaging (fMRI). The primary safety outcome will be assessed at 4 months, and adverse events will be recorded.

Discussion

This study represents the clinical investigation into the efficacy of therapeutic LIPUS in the treatment of PD for the first time. If LIPUS is determined to be effective, it could offer a practical and innovative means of expanding the accessibility of ultrasound therapy by using a wearable LIPUS device within a home setting.

Trial registration

Chinese Clinical Trial Registry ChiCTR2100052093. Registered on 17 October 2021.
Appendix
Available only for authorised users
Literature
1.
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60.PubMedCrossRef
2.
Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–90.PubMedCrossRef
3.
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.PubMedCrossRef
4.
GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53.CrossRef
5.
Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–5.PubMedCrossRef
6.
Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–66.PubMedCrossRef
7.
Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–83.PubMedCrossRef
8.
9.
Krack P, Martinez-Fernandez R, Del Alamo M, et al. Current applications and limitations of surgical treatments for movement disorders. Mov Disord. 2017;32(1):36–52.PubMedCrossRef
10.
Jiang X, Savchenko O, Li Y, et al. A review of low-intensity pulsed ultrasound for therapeutic applications. IEEE Trans Biomed Eng. 2019;66(10):2704–18.PubMedCrossRef
11.
12.
13.
Barnett SB, Ter Haar GR, Ziskin MC, et al. International recommendations and guidelines for the safe use of diagnostic ultrasound in medicine. Ultrasound Med Biol. 2000;26(3):355–66.PubMedCrossRef
14.
Martínez-Fernández R, Máñez-Miró JU, Rodríguez-Rojas R, et al. Randomized trial of focused ultrasound subthalamotomy for Parkinson’s disease. N Engl J Med. 2020;383(26):2501–13.PubMedCrossRef
15.
Bond AE, Shah BB, Huss DS, et al. Safety and efficacy of focused ultrasound thalamotomy for patients with medication-refractory, tremor-dominant Parkinson disease: a randomized clinical trial. JAMA Neurol. 2017;74(12):1412–8.PubMedPubMedCentralCrossRef
16.
Quadri SA, Waqas M, Khan I, et al. High-intensity focused ultrasound: past, present, and future in neurosurgery. Neurosurg Focus. 2018;44(2):E16.PubMedCrossRef
17.
Dallapiazza RF, Timbie KF, Holmberg S, et al. Noninvasive neuromodulation and thalamic mapping with low-intensity focused ultrasound. J Neurosurg. 2018;128(3):875–84.PubMedCrossRef
18.
Zhong YX, Liao JC, Liu X, et al. Low intensity focused ultrasound: a new prospect for the treatment of Parkinson’s disease. Ann Med. 2023;55(2):2251145.PubMedPubMedCentralCrossRef
19.
Tufail Y, Matyushov A, Baldwin N, et al. Transcranial pulsed ultrasound stimulates intact brain circuits. Neuron. 2010;66(5):681–94.PubMedCrossRef
20.
Bystritsky A, Korb AS, Douglas PK, et al. A review of low-intensity focused ultrasound pulsation. Brain Stimul. 2011;4(3):125–36.PubMedCrossRef
21.
Fomenko A, Neudorfer C, Dallapiazza RF, et al. Low-intensity ultrasound neuromodulation: an overview of mechanisms and emerging human applications. Brain Stimul. 2018;11(6):1209–17.PubMedCrossRef
22.
Sung CY, Chiang PK, Tsai CW, et al. Low-intensity pulsed ultrasound enhances neurotrophic factors and alleviates neuroinflammation in a rat model of Parkinson’s disease. Cereb Cortex. 2021;32(1):176–85.PubMedCrossRef
23.
Zhou H, Niu L, Xia X, et al. Wearable ultrasound improves motor function in an MPTP mouse model of Parkinson’s disease. IEEE Trans Biomed Eng. 2019;66(11):3006–13.PubMedCrossRef
24.
Song WS, Sung CY, Ke CH, et al. Anti-inflammatory and neuroprotective effects of transcranial ultrasound stimulation on Parkinson’s disease. Ultrasound Med Biol. 2022;48(2):265–74.PubMedCrossRef
25.
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurol. 2006;5(1):75–86.PubMedCrossRef
26.
27.
Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008;7(11):1044–55.PubMedCrossRef
28.
Go CL, Frenzel A, Rosales RL, et al. Assessment of substantia nigra echogenicity in German and Filipino populations using a portable ultrasound system. J Ultrasound Med. 2012;31(2):191–6.PubMedCrossRef
29.
Fahn S, Elton RL, UPDRS program members. Unified Parkinsons disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Recent developments in Parkinsons disease, vol. 2. Florham: Macmillan Healthcare Information; 1987. p. 153–63.
30.
Martinez-Martin P, Gil-Nagel A, Gracia LM, et al. Unified Parkinson’s disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord. 1994;9:76–83.PubMedCrossRef
31.
Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. Appl Nurs Res. 2000;13(4):209–13.PubMedCrossRef
32.
Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.PubMedCrossRef
33.
Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck anxiety inventory and its factors as a screener for anxiety disorders. J Anxiety Disord. 2006;20(4):444–58.PubMedCrossRef
34.
Markser A, Maier F, Lewis CJ, et al. Deep brain stimulation and cognitive decline in Parkinson’s disease: the predictive value of electroencephalography. J Neurol. 2015;262(10):2275–84.PubMedCrossRef
35.
Prodoehl J, Burciu RG, Vaillancourt DE. Resting state functional magnetic resonance imaging in Parkinson’s disease. Curr Neurol Neurosci Rep. 2014;14(6):448.PubMedCrossRef
36.
Schrag A, Sampaio C, Counsell N, et al. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord. 2006;21(8):1200–7.PubMedCrossRef
37.
Sedgwick P. Intention to treat analysis versus per protocol analysis of trial data. BMJ. 2015;350:h681.PubMedCrossRef
38.
39.
Krishna V, Fishman PS, Eisenberg HM, et al. Trial of globus pallidus focused ultrasound ablation in Parkinson’s disease. N Engl J Med. 2023;388(8):683–93.PubMedCrossRef
40.
Martínez-Fernández R, Rodríguez-Rojas R, Del Álamo M, et al. Focused ultrasound subthalamotomy in patients with asymmetric Parkinson’s disease: a pilot study. Lancet Neurol. 2018;17(1):54–63.PubMedCrossRef
41.
Sinai A, Nassar M, Sprecher E, et al. Focused ultrasound thalamotomy in tremor dominant Parkinson’s disease: long-term results. J Parkinsons Dis. 2022;12(1):199–206.PubMedPubMedCentralCrossRef
42.
Hayner M, Hynynen K. Numerical analysis of ultrasonic transmission and absorption of oblique plane waves through the human skull. J Acoust Soc Am. 2001;110(6):3319–30.PubMedCrossRef
43.
Metadata
Title
Efficacy of Wearable low-intensity pulsed Ultrasound treatment in the Movement disorder in Parkinson’s disease (the SWUMP trial): protocol for a single-site, double-blind, randomized controlled trial
Authors
Chuanyu Zhong
Ning Guo
Canfang Hu
Ruilong Ni
Xiaojie Zhang
Zheying Meng
Taotao Liu
Siqi Ding
Wanhai Ding
Yuwu Zhao
Li Cao
Yuanyi Zheng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Trials / Issue 1/2024
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-024-08092-y

Other articles of this Issue 1/2024

Trials 1/2024 Go to the issue

Study protocol

mini-MED: study protocol for a randomized, multi-intervention, semi-controlled feeding trial of a Mediterranean-amplified vs. habitual Western dietary pattern for the evaluation of food-specific compounds and cardiometabolic health

Research

Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

Research

Comparing the effects of pulsed and radiofrequency catheter ablation on quality of life, anxiety, and depression of patients with paroxysmal supraventricular tachycardia: a single-center, randomized, single-blind, standard-controlled trial

Study protocol

An e-mental health intervention to reduce depression symptoms in individuals with obesity: study protocol for the randomized, controlled, two-armed, confirmatory LightMood trial

Study protocol

Comparison of hemostatic ability between spray coagulation and forced coagulation modes in endoscopic submucosal dissection in patients with early gastric neoplasms: a study protocol for multicenter randomized controlled trial (Spray-G trial)

Study protocol

The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries